Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ≥ 18 years with type 1 or 2 diabetes mellitus~* Subjects with diabetic macular edema (DME) secondary to diabetes mellitus involving the center of the macula in the study eye~* Decrease in vision determined to be primarily the result of DME in the study eye~* Best-corrected visual acuity (BCVA) early treatment diabetic retinopathy study (ETDRS) letter score of 73 to 24 (20/40 to 20/320) in the study eye~Exclusion Criteria:~* Laser photocoagulation (panretinal or macular) in the study eye within 90 days of Day 1~* More than 2 previous macular laser treatments in the study eye~* Previous use of intraocular or periocular corticosteroids in the study eye within 120 days of Day 1~* Previous treatment with antiangiogenic drugs in either eye (pegaptanib sodium, bevacizumab, ranibizumab etc.) within 90 days of Day 1~* Active proliferative diabetic retinopathy (PDR) in the study eye~* Uncontrolled diabetes mellitus, as defined by HbA1c \>12%~* Only 1 functional eye even if that eye is otherwise eligible for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravitreal Aflibercept Injection 2Q4 (Type: EXPERIMENTAL): Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF \[vascular endothelial growth factor\] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.
- Intravitreal Aflibercept Injection 2Q8 (Type: EXPERIMENTAL): Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.
- Macular Laser Photocoagulation (Type: ACTIVE_COMPARATOR): Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).